RecruitingNCT07072143
An International Study on Pediatric Patients With Rare Tumors.
The PARTNER Study - An International Prospective Observational Study on Pediatric Patients With Very Rare Tumors.
Sponsor
Azienda Ospedaliera di Padova
Enrollment
6,250 participants
Start Date
Jan 25, 2025
Study Type
OBSERVATIONAL
Conditions
MesotheliomaThyroid CarcinomaPleuropulmonary BlastomaMelanoma and Other Malignant Neoplasms of SkinNUT CarcinomaParaganglioma/ PhaeochromocytomaGastrointestinal Stromal Tumor (GIST)Adrenocortical TumorPancreatic TumorsEsthesioneuroblastoma, OlfactoryNasopharyngeal Carcinoma (NPC)Salivary Gland TumorsThymic TumorsAppendiceal Cancers
Summary
The PARTNER study is an international, prospective, observational study of paediatric patients with very rare tumours.
Eligibility
Min Age: 0 YearsMax Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This international study collects clinical data on children and teenagers with rare tumors that are not commonly studied due to their low incidence. The goal is to build a large database to better understand these cancers and improve future treatment options.
**You may be eligible if...**
- You are a child or adolescent between 0 and 18 years old
- You have been diagnosed with a primary or relapsed rare tumor
- You are treated at a participating center
- A parent or legal guardian has given written consent
**You may NOT be eligible if...**
- Written consent from a parent or legal guardian has not been obtained
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07072143
Related Trials
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
NCT077053343 locations
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
NCT0727741316 locations
DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study
NCT012475972 locations
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
NCT0578692427 locations
Dynamic Risk Prediction of Severe Myelosuppression in Nasopharyngeal Carcinoma
NCT07819656